Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    NCT02630901
Previous Study | Return to List | Next Study

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Prothena Biosciences Limited
Sponsor:
Information provided by (Responsible Party):
Prothena Biosciences Limited
ClinicalTrials.gov Identifier:
NCT02630901
First received: December 11, 2015
Last updated: December 6, 2016
Last verified: September 2016
  Purpose
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 56 patients with Psoriasis.

Condition Intervention Phase
Psoriasis
Drug: PRX003
Other: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Subjects With Psoriasis

Resource links provided by NLM:


Further study details as provided by Prothena Biosciences Limited:

Primary Outcome Measures:
  • Safety and tolerability as determined by number of subjects with adverse events [ Time Frame: 6 months ]
  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    time of the maximum measured concentration (Tmax)

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    maximum concentration (Cmax)

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    elimination rate constant

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    terminal elimination half life (t½)

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    clearance (CL)

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    apparent volume of distribution (Vd)

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    average concentration over a dosing interval (Cav)

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    area under the plasma concentration-time curve for a dosing interval (AUCtau)

  • Determination of pharmacokinetics parameters [ Time Frame: 20 weeks ]
    minimum observed concentration (Cmin)


Secondary Outcome Measures:
  • Immunogenicity as determined by measurement of anti-PRX003 antibodies [ Time Frame: 20 weeks ]
    antibody titers will be listed and summarized


Estimated Enrollment: 56
Study Start Date: March 2016
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PRX003 Drug: PRX003
Placebo Comparator: Placebo Other: Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, 18 to 80 years of age (inclusive), body weight range of ≥ 45 kg (99 lbs) to ≤ 120 kg (264 lbs) and a body mass index (BMI) of 18 - 35 kg/m2
  2. Provide written informed consent
  3. PASI score of ≥12
  4. Plaque psoriasis covering ≥10% of BSA
  5. s-PGA score of 3 or 4
  6. Able to perform all protocol-specified assessments and comply with the study visit schedule
  7. Female subjects who are not postmenopausal or surgically sterile must use physician approved contraception for at least 60 days prior to Baseline (Day 1/Visit 2) to 12 weeks following the last study drug administration. Unless they are at least 2 years postmenopausal or surgically sterile, women must have a pregnancy test with follicle stimulating hormone (FSH) >40 IU/L and estradiol <20 pg/mL (unless on hormone-replacement therapy). Women of childbearing potential must be non lactating and have a negative serum pregnancy test (beta human chorionic gonadotropin [β HCG]) at Screening (Visit 1).
  8. If male, must be surgically sterile or must agree to use physician-approved contraception from Baseline (Day 1/Visit 2) to 12 weeks following the last study drug administration

Exclusion Criteria:

  1. Presents with psoriasis that is predominantly guttate, erythrodermic, inverse, pustular or palmo-plantar, or an unstable form of psoriasis
  2. Receipt of any of the following within the specified time frame prior to Baseline (Day 1/Visit 2):

    • Topical psoriasis treatments (other than low-potency topical corticosteroids or emollients, which are permitted during the study) within 2 weeks
    • Systemic (nonbiologic) psoriasis treatments within 4 weeks or 5 half-lives (whichever is longer)
    • Biologic psoriasis treatments within 12 weeks or 5 half-lives (whichever is longer)
    • Drugs that appear to have a strong causal relationship to psoriasis (e.g., beta-blockers and lithium) within 4 weeks or 5 half-lives (whichever is longer)
    • Phototherapy within 4 weeks
  3. Participation in recreational sunbathing or use of a sun-bed (e.g., tanning salon) within 7 days prior to Baseline (Day 1)
  4. Any major medical illness or unstable medical condition that, in the opinion of the Investigator or Sponsor, may interfere with the subject's ability to comply with study procedures or abide by study restrictions, or with the ability to interpret safety data, including, but not limited to:

    • Within 5 years of Screening (Visit 1)
    • History of cancer with the exception of fully excised non-melanoma skin cancer
    • History of stroke
    • History of epilepsy or seizure disorder other than febrile seizures as a child, or any seizure or loss of consciousness
    • History of or active autoimmune disease (other than psoriasis or PsA)
    • Within 2 years of Screening (Visit 1)
    • Myocardial infarction
    • Clinically significant cardiovascular disease including any of the following: unstable angina, decompensated congestive heart failure, clinically significant arrhythmias
    • Vascular diseases, including, but not limited to, blood clotting disorders, atherosclerosis, aneurysms, and renal artery disease
  5. Hypotension (systolic blood pressure [BP] ≤85 millimeters of mercury [mmHg]) at Baseline (Day 1/Visit 2) predose or a known history or documentation of hypotension on more than one occasion within 3 months prior to Baseline (Day 1/Visit 2)
  6. Uncontrolled hypertension as indicated by a resting systolic BP ≥150 mmHg or diastolic BP ≥95 mmHg at Screening (Visit 1) or Baseline (Day 1/Visit 2) predose or a known history or documentation of uncontrolled hypertension on more than one occasion within 3 months prior to Baseline (Day 1/Visit 2)
  7. Clinically significant systemic infection (e.g., chronic or acute infection, urinary tract infection, upper respiratory infection) within 30 days of Baseline (Day 1/ Visit 2), or a history or presence of recurrent or chronic infection (e.g., viral infections [including hepatitis B or C, human immunodeficiency virus (HIV)], bacterial infections, systemic fungal infections, or syphilis)
  8. History of any inflammatory bowel disease
  9. Any current psychiatric diagnosis according to Diagnostic and Statistical Manual of Mental Disorders IV Text Revision (DSM-IV-TR) that may interfere with the subject's ability to perform the study and all assessments (e.g., alcohol or drug-related abuse or alcohol dependence, or alcohol or drug-related dementia, major depression, developmental disability, schizophrenia, bipolar disorder). Note: Subjects with adequately controlled depression for at least 6 months are not excluded; however, suicidal ideation or attempt at any time within the past year is exclusionary.
  10. A positive tuberculosis skin test (TST) or a positive interferon-gamma release assay (IGRA) during Screening (Visit 1).

    Note: In the event a subject has had a TST or IGRA within 3 months before Baseline (Day 1/Visit 2), this does not need to be repeated during screening and the previous result can be carried forward and used in this study.

    Prior standard treatment for latent tuberculosis and prior exposure to tuberculosis with subsequent standard prophylactic treatment is allowed if recent (within ˂ 30 days) negative chest X-ray.

  11. Any of the following laboratory abnormalities at Screening (Visit 1):

    • Total bilirubin (unless attributed to Gilbert's syndrome) >1.5 times the upper limit of normal (× ULN), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 × ULN
    • Serum creatinine >133 µmol/L (1.5 mg/dL)
    • Hemoglobin <11.5 g/dL for males or <10.0 g/dL for females, absolute neutrophil count of ˂1500/µL (with the exception of a documented history of a chronic benign neutropenia), or platelet count of <120,000/µL
  12. Use of an investigational product or device or participation in a drug research study within a period of 30 days (or 5 half-lives of the drug, whichever is longer) prior to Screening (Visit 1); for investigational products or drug research studies relating to psoriasis or arthritis, the duration will be extended to 12 weeks (or 5 half-lives of the drug, whichever is longer) prior to Screening (Visit 1)
  13. Allergy to any of the components of PRX003 such as histidine, sucrose and polysorbate 20
  14. Receipt of any vaccine (with the exception of seasonal influenza) within 30 days prior to Screening (Visit 1)
  15. Donation of >500 mL of blood within 3 months prior to Screening (Visit 1)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02630901

Contacts
Contact: Bree Martin bree.martin@prothena.com

Locations
United States, California
TCR Medical Corporation Recruiting
San Diego, California, United States, 92123
United States, Florida
Universal Medical and Research Center, LLC Recruiting
Coral Gables, Florida, United States
Renstar Medical Research Recruiting
Ocala, Florida, United States, 34471
United States, Ohio
University Hospitals Case Medical Center Recruiting
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
Altoona Center for Clinical Research Recruiting
Duncansville, Pennsylvania, United States, 16635
UPMC Department of Dermatology Recruiting
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
Dermatology Treatment and Research Center, PA Recruiting
Dallas, Texas, United States
Clinical Trials of Texas, Inc. Recruiting
San Antonio, Texas, United States
United States, Virginia
Virginia Clinical Research Inc. Recruiting
Norfolk, Virginia, United States, 23502
Sponsors and Collaborators
Prothena Biosciences Limited
  More Information

Responsible Party: Prothena Biosciences Limited
ClinicalTrials.gov Identifier: NCT02630901     History of Changes
Other Study ID Numbers: PRX003-102
Study First Received: December 11, 2015
Last Updated: December 6, 2016
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases

ClinicalTrials.gov processed this record on May 25, 2017